Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oramed Pharmaceuticals Inc.

www.oramed.com

Latest From Oramed Pharmaceuticals Inc.

Pipeline Watch: Phase III Starts With VX-445, Reproxalap And AVXS-101

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

USV Seeks To Progress Oral Insulin In India

USV Ltd expects to progress studies with Diabetology’s oral insulin in India, five years after the companies signed a licensing deal in 2012. The oral insulins space has seen mixed progress in the recent past, with a high profile pullback and funding support in another instance for an oral insulin candidate.

Research & Development Metabolic Disorders

Biocon’s Oral Insulin Gains Momentum With JDRF Backing

Biocon’s oral insulin program has received a boost with the US-based JDRF supporting plans to progress its drug candidate in type 1 diabetes. While the pullback of players like Novo Nordisk underscores the potential risks in the oral insulin space, JDRF says early results of Biocon’s candidate “warrant support” for further studies.

Metabolic Disorders Deals

Novo Still Seeking Superior Tresiba Follow-On, Says CSO

Despite dropping its Phase II oral insulin program in the second half of 2016, Novo Nordisk's chief scientific officer says the company is quietly continuing to explore options for an oral therapy better than its leading insulin option, Tresiba.

Business Strategies Metabolic Disorders
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Oramed Pharmaceuticals Inc.
  • Senior Management
  • Nadav Kidron, Pres. & CEO
    Hilla Eisenberg, CFO
    Miriam Kidron, PhD, CSO
    Joshua Hexter, COO & VP, Bus. Dev.
  • Contact Info
  • Oramed Pharmaceuticals Inc.
    Phone: (972)(646) 844-1164
    142 W. 57th St., 11th F.
    New York, NY 10019
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register